to each IOL material used in each of the 4 countries. RESULTS: Ranking the materials in the countries shows that hydrophobic acrylic is number one in all the countries except Germany where it was second. PMMA had the best ratio in Germany, was second in Spain and only third in Italy and France. Silicone was second in France and ranked third in the other countries. Hydrophilic had the worst ratio overall in all countries. CONCLUSIONS: Cost effectiveness ratios of hydrophobic acrylic were better than those of the other types of IOL materials used in most countries. Sensitivity analyses were performed to vary the base case analysis to demonstrate the economic importance of the assumptions. In all cases, acrylic hydrophobic IOL material was shown to be a costeffective option. Resource data were assigned economic valuation to determine direct costs from the third-party payer perspective. Multiple regression analyses were then performed to identify the main cost drivers in treatment.
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A MULTI-CENTER
RESULTS:
The total average annual direct cost of treating glaucoma was estimated at €467 patient for all patients. In Sweden, the total annual direct cost was higher than in France (€531 patient vs. €390 patient). Glaucoma medication costs comprised 49% of total direct cost in both countries. Results from the linear regression analysis indicated that patients with the greatest severity categories had drug costs that are 1.8-3.0 times higher, and total costs 3.6 times higher than for less severe patients. Patients with higher baseline IOPs were found to have higher average treatment costs. CON-CLUSIONS: Glaucoma treatment costs in Europe are particularly significant for end-stage and higher baseline IOPs patients. Treatment costs represent a substantial proportion of direct costs. These findings suggest that therapies targeted at efficient IOP control slowing disease progression will prove to be the most cost-efficient. 
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PSYCHOMETRIC VALIDATION OF THE NEI-VFQ 25 FRENCH VERSION IN A POPULATION OF PATIENTS TREATED FOR OCULAR HYPERTENSION AND GLAUCOMA
